Innate Pharma (NASDAQ:IPHA) Earns “Buy” Rating from HC Wainwright

Innate Pharma (NASDAQ:IPHA)‘s stock had its “buy” rating restated by HC Wainwright in a report issued on Thursday,Benzinga reports. They presently have a $11.50 price objective on the stock. HC Wainwright’s price objective would indicate a potential upside of 489.74% from the stock’s current price.

Innate Pharma Price Performance

Shares of IPHA opened at $1.95 on Thursday. Innate Pharma has a 1 year low of $1.29 and a 1 year high of $3.51. The company has a 50 day simple moving average of $1.84 and a two-hundred day simple moving average of $1.98.

Innate Pharma Company Profile

Innate Pharma SA, a biotechnology company, develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; IPH5201, a blocking antibody that is in Phase II clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway to promote antitumor immunity; IPH6401, an BCMA-targeting NK cell engager; and IPH6101, a NKp46-based NK cell engager that targets CD123 proprietary multi-specific antibody format; and IPH62, an B7-H3-targeting NK cell engager.